01—Abstract
Summary
Summary of the 8-K filed May 7, 2025. Cited figures are marked; the original filing is the authoritative source.
BeiGene, Ltd. (NASDAQ: ONC), which is in the process of renaming itself BeOne Medicines Ltd. and redomiciling to Switzerland, reported first quarter 2025 results on May 7, 2025 that marked its first quarter of GAAP profitability.
Total revenue rose 49% year over year to $1.117 billiona, driven by BRUKINSA (zanubrutinib) global sales of $792 million, up 62%, with U.S. BRUKINSA sales of $563 million (up 60%) and European sales of $116 million (up 73%). Product revenue was $1.109 billion, and TEVIMBRA contributed $171 million, up 18%. Profitability improved sharply.
GAAP income from operations was $11.1 millionb versus a $261.3 million loss a year earlier, and GAAP net income was $1.3 million ($0.01 per diluted ADS). Non-GAAP adjusted operating income was $139.4 million and adjusted diluted EPS per ADS was $1.22. Gross margin improved to 85.1% on a GAAP basis, and operating cash flow was $44 million, a $353 million swing from the prior-year outflow.
Cash, cash equivalents and restricted cash declined to $2.53 billion, and debt fell to $924 millionc from $1.02 billion at year-end 2024. Management maintained full-year 2025 guidance of $4.9 to $5.3 billion in total revenue and $4.1 to $4.4 billion in GAAP operating expenses, and reiterated targets for a mid-80% gross margin, positive full-year GAAP operating income and positive operating cash flow.
For investors, the key takeaways are the transition from losses to GAAP profitability, the continued commercial momentum of BRUKINSA, and the thin GAAP margin in a single quarter, which still depends on sustaining revenue growth against rising R&D and SG&A spending. The quarter also featured an impairment of equity investments of $12.4 milliond, a favorable Pharmacyclics patent decision, and upcoming catalysts including an Investor R&D Day on June 26, 2025 and several Phase 3 readouts later in 2025.
02—Key points
Key Highlights
- Total revenue up 49% year over year to $1.117 billion; BRUKINSA global sales up 62% to $792 million, with U.S. BRUKINSA sales up 60% to $563 million.
- First quarter of GAAP profitability: GAAP net income of $1.3 million versus a $251.2 million loss in Q1 2024; GAAP diluted EPS of $0.01 per ADS.
- Operating cash flow of $44 million, a $353 million improvement from the prior-year period's outflow of $309 million.
- Gross margin improved to 85.1% (GAAP) from 83.3%, supported by BRUKINSA's higher sales mix and cost-of-sales productivity gains.
- Debt reduced to $924 million from $1.02 billion at December 31, 2024; cash and restricted cash of $2.53 billion at quarter end.
- Full-year 2025 guidance maintained: total revenue of $4.9–5.3 billion, GAAP operating expenses of $4.1–4.4 billion, and positive full-year GAAP operating income and operating cash flow.
- Catalysts ahead: Investor R&D Day on June 26, 2025; Phase 3 readouts and approvals across sonrotoclax, BGB-16673, tablet BRUKINSA and TEVIMBRA; shareholder approval obtained for the BeOne Medicines name change and Swiss redomiciliation.
03—Questions
Frequently Asked Questions
Did BeiGene actually turn a GAAP profit in Q1 2025?
Yes, but only narrowly. GAAP net income was $1.27 million, or $0.01 per diluted ADS, compared with a net loss of $251.2 million in Q1 2024. GAAP income from operations was $11.1 million. Management described this as the company's first quarter of GAAP profitability, though the margin was very thin and the result depended on continued revenue growth.
What is driving revenue growth?
BRUKINSA is the main driver, with global sales of $792 million (up 62%). Growth came from demand in the U.S., where BRUKINSA became the leader in new chronic lymphocytic leukemia (CLL) patient starts across all lines and the overall BTK inhibitor market share leader for the first time, as well as from Europe, where sales rose 73%. TEVIMBRA sales of $171 million (up 18%) and in-licensed Amgen products also contributed.
Is the company's full-year 2025 outlook changing?
No. BeiGene maintained its full-year 2025 guidance: total revenue of $4.9–5.3 billion, GAAP operating expenses of $4.1–4.4 billion, a mid-80% gross margin, positive full-year GAAP operating income and positive operating cash flow. The guidance excludes any new material business development activity or unusual or non-recurring items.
What do the non-GAAP figures add, and how do they differ from GAAP?
Adjusted figures exclude share-based compensation, depreciation, amortization and certain special items. Adjusted operating income was $139.4 million versus GAAP operating income of $11.1 million, and adjusted diluted EPS per ADS was $1.22 versus GAAP $0.01. The gap is mainly $95.5 million of share-based compensation and $31.6 million of depreciation. Investors should weigh GAAP results heavily, since share-based compensation is a real economic cost.
What corporate and pipeline events should investors watch?
The company plans to rename itself BeOne Medicines Ltd. and redomicile to Switzerland, with closing expected later in 2025 after shareholder approval on April 28, 2025. An Investor R&D Day is set for June 26, 2025, focused on breast cancer and solid tumors. Key 2H 2025 milestones include the MANGROVE interim analysis for treatment-naïve MCL, the Phase 3 zanidatamab readout in HER2-positive gastroesophageal adenocarcinoma, and sonrotoclax MCL accelerated approval submissions. The company also discontinued ociperlimab in lung cancer.
04—Continue